Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 1
2014 1
2015 1
2016 1
2018 1
2019 1
2020 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
Bidard FC, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, Goncalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero JM, Loirat D, Cabel L, Kadi A, Diéras V, Alix-Panabières C, Pierga JY. Bidard FC, et al. J Clin Oncol. 2024 Feb 1;42(4):383-389. doi: 10.1200/JCO.23.00456. Epub 2023 Nov 6. J Clin Oncol. 2024. PMID: 37931185 Clinical Trial.
Median OS was 51.3 months (95% CI, 46.8 to 55.1) in the CTC arm and 45.5 months (95% CI, 40.9 to 51.1) in the standard arm (hazard ratio [HR] for death, 0.85; 95% CI, 0.69 to 1.03; P = .11). Among 189 patients (25.0%) with ET recommended by clinicians and high CTC count, c …
Median OS was 51.3 months (95% CI, 46.8 to 55.1) in the CTC arm and 45.5 months (95% CI, 40.9 to 51.1) in the standard arm (hazard ratio [HR …
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. Torregrosa C, et al. Int J Cancer. 2022 Dec 1;151(11):1978-1988. doi: 10.1002/ijc.34166. Epub 2022 Jul 14. Int J Cancer. 2022. PMID: 35833561 Free article.
After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6 …
After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab …
Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations.
Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, Le Roux E, Bernède-Bauduin C, Le Bourgeois M, Herrmann JL, Guillemot D, Gaillard JL; OMA group. Catherinot E, et al. J Cyst Fibros. 2013 Jan;12(1):74-80. doi: 10.1016/j.jcf.2012.06.009. Epub 2012 Jul 31. J Cyst Fibros. 2013. PMID: 22857820 Free article.
RESULTS: MAC-positive patients were significantly older than MABSC-positive patients (mean [SD] age, 23.1 [10.2] vs 17.4 [8.3] years, p=0.013), and were also older at CF diagnosis (mean [SD] age, 12.9 [16.1] vs 3.1 [7.7] years, p=0.015); they tended to be less frequ …
RESULTS: MAC-positive patients were significantly older than MABSC-positive patients (mean [SD] age, 23.1 [10.2] vs 17.4 [8.3] years, p …
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators. Dohan A, et al. Gut. 2020 Mar;69(3):531-539. doi: 10.1136/gutjnl-2018-316407. Epub 2019 May 17. Gut. 2020. PMID: 31101691
RESULTS: In the training cohort, the significant predictive features for OS were: decrease in sum of the target liver lesions (STL), (adjusted hasard-ratio(aHR)=13.7, p=1.9310(-7)), decrease in kurtosis (ssf=4) (aHR=1.08, p=0.001) and high baseline density of DLL, ( …
RESULTS: In the training cohort, the significant predictive features for OS were: decrease in sum of the target liver lesions (STL), (adjust …
Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.
Roux AL, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, Chiron R, Fauroux B, Le Bourgeois M, Munck A, Pin I, Sermet I, Gutierrez C, Véziris N, Jarlier V, Cambau E, Herrmann JL, Guillemot D, Gaillard JL; OMA group. Roux AL, et al. J Cyst Fibros. 2015 Jan;14(1):63-9. doi: 10.1016/j.jcf.2014.07.004. Epub 2014 Jul 30. J Cyst Fibros. 2015. PMID: 25085077 Free article.
RESULTS: M. massiliense cases were younger than M. abscessus cases (mean age: 12.8 vs 17.1 years; p=0.02) at the time of the first mycobacterial isolation and also had lower body mass index values (mean: 16.4 vs 19.3 kg/m(2), p=0.002). All M. massiliense cases, exce …
RESULTS: M. massiliense cases were younger than M. abscessus cases (mean age: 12.8 vs 17.1 years; p=0.02) at the time of the first my …
Vascular access sites for acute renal replacement in intensive care units.
Dugué AE, Levesque SP, Fischer MO, Souweine B, Mira JP, Megarbane B, Daubin C, du Cheyron D, Parienti JJ; Cathedia Study Group. Dugué AE, et al. Clin J Am Soc Nephrol. 2012 Jan;7(1):70-7. doi: 10.2215/CJN.06570711. Epub 2011 Nov 10. Clin J Am Soc Nephrol. 2012. PMID: 22076877 Free PMC article. Clinical Trial.
Using anatomic landmarks, time to insert a femoral catheter was shorter (P=0.01) and more successful (P=0.003) compared with catheterization in the jugular site. ...No significant difference (P=0.49) in mean URR was detected between sessions performed through …
Using anatomic landmarks, time to insert a femoral catheter was shorter (P=0.01) and more successful (P=0.003) compared with c …
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators. Aparicio T, et al. Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26. Eur J Cancer. 2018. PMID: 29807237 Free article.
Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months, HR = 0.88 [0.80-0.98] p = 0.02) and objective response rate (ORR) (42% versus 36% OR = 1.23 [1.01-1.50] p …
Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 …
Continuous renal replacement therapy may increase the risk of catheter infection.
Parienti JJ, Dugué AE, Daurel C, Mira JP, Mégarbane B, Mermel LA, Daubin C, du Cheyron D; Members of the Cathedia Study Group. Parienti JJ, et al. Clin J Am Soc Nephrol. 2010 Aug;5(8):1489-96. doi: 10.2215/CJN.02130310. Epub 2010 Jun 17. Clin J Am Soc Nephrol. 2010. PMID: 20558562 Free PMC article.

The incidence of catheter-tip colonization per 1000 catheter-days was 42.7 in the IHD group and 27.7 in the CRRT group (P < 0.01). This association was no longer significant after correction for channeling bias (weighted HR, 0.96; 95% CI: 0.77 to 1.20, P = 0.73).

…

The incidence of catheter-tip colonization per 1000 catheter-days was 42.7 in the IHD group and 27.7 in the CRRT group (P < 0.01).

…
Nonsteroidal Anti-Inflammatory Drug without Antibiotics for Acute Viral Infection Increases the Empyema Risk in Children: A Matched Case-Control Study.
Le Bourgeois M, Ferroni A, Leruez-Ville M, Varon E, Thumerelle C, Brémont F, Fayon MJ, Delacourt C, Ligier C, Watier L, Guillemot D; Children, Antibiotics, Nonsteroidal Anti-inflammatory Drugs and Childhood Empyema (ChANCE) Study Group. Le Bourgeois M, et al. J Pediatr. 2016 Aug;175:47-53.e3. doi: 10.1016/j.jpeds.2016.05.025. Epub 2016 Jun 20. J Pediatr. 2016. PMID: 27339249 Free PMC article. Clinical Trial.
Considering the intake of any drug within 72 hours after acute viral infection onset and at least 6 consecutive days of antibiotic use and at least 1 day of NSAIDs exposure, the multivariable analysis retained an increased risk of empyema associated with NSAIDs exposure (aOR 2.79 …
Considering the intake of any drug within 72 hours after acute viral infection onset and at least 6 consecutive days of antibiotic use and a …